US Stock MarketDetailed Quotes
IFRX InflaRx
- 1.410
- +0.040+2.92%
Close May 1 16:00 ET
83.03MMarket Cap-1686P/E (TTM)
1.430High1.330Low197.27KVolume1.365Open1.370Pre Close275.03KTurnover0.40%Turnover RatioLossP/E (Static)58.88MShares5.20052wk High0.76P/B68.84MFloat Cap1.14052wk Low--Dividend TTM48.82MShs Float53.100Historical High--Div YieldTTM7.30%Amplitude0.776Historical Low1.394Avg Price1Lot Size
About InflaRx Company
InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR. Its primary product candidate is Vilobelimab. The company was founded by Niels Christoph Riedemann, Renfeng Guo, and Nicolas Fulpius in December 2007 and is headquartered in Jena, Germany.
Company Profile
SymbolIFRX
Company NameInflaRx
Listing DateNov 8, 2017
Issue Price15.00
Founded2007
CEOProfessor Niels Riedemann
MarketNASDAQ
Employees66
Securities TypeOrdinary Shares
Fiscal Year Ends12-31
AddressWinzerlaer Strasse 2
CityJena
ProvinceThueringen
CountryGermany
Zip Code07745
Phone49-36-41-508180
Websitehttp://www.inflarx.de
Company Executives
- Name
- Position
- Salary
- Professor Niels Riedemann
- Executive Director and Chief Executive Officer
- --
- Dr. Thomas Taapken
- Chief Financial Officer
- --
- Professor Dr. Renfeng Guo, M.D.
- Executive Director and Chief Scientific Officer
- --
- Dr. Camilla Chong
- Chief Medical Officer
- --
- Derval O’Carroll
- Senior Vice President and Global Head, Regulatory Affairs and Compliance
- --
- Nicolas Fulpius
- Non-Executive Chairman of the Board
- --
- Hege Hellstrom
- Director
- --
- Richard H. Brudnick
- Independent Director
- --
- Mark Kubler
- Independent Director
- --
- Anthony Gibney
- Independent Director
- --
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg